Austin Startup: Lumos Pharma To Develop & Prepare Autism Treatment Discovered In Cincinnati

There may be some great news for parents of Autistic boys in the coming years.

A research team at the University of Cincinnati has announced that they’ve successfully treated an animal model of Creatine Transporter Deficiency (CTD). CTD is what causes Autism in boys. Over 50,000 boys in the US are afflicted with CTD.

Creatine Transporter Deficiency causes symptoms including seizures, mental retardation and speech defects.

CTD was discovered at Children’s Hospital in Cincinnati in 2000. Almost all of the research on CTD has been performed at Children’s Hospital and at the University of Cincinnati.

This is actually a wonderful, tremendous Cincinnati-centric story,” Joe Clark the UC Neurology Professor who led the research team said to “The disease was discovered at Children’s Hospital, the animal model of the disease was made here in Cincinnati by UC, and the drug was made to treat those mice here at Cincinnati.”

The research team found that cyclocreatine, which has been dubbed CincY, has been incredibly effective at reducing the symptoms of CTD models in animals.

Clark reported that the time from discovery in 2000 to the discovery of this possible treatment in just twelve years was actually a rather short time frame. While this work has been done on animals, it may be another two to three years befor CincY can be used to treat humans.

Clark is quick to point out that this is just a treatment for the disease and not a cure.

“Essentially, a cure is fixing a broken pipe at the break, and a treatment is making a bypass around the afflicted area without fixing it, but in a manner that eliminates the symptoms” Clark said.



Nibletz is the voice of startups “everywhere else”



You Might Also Like